# Amrutanjan Health Care share price today (Amrutanjan Health Care Ltd, NSE: AMRUTANJAN)

> Amrutanjan Health Care share price today: ₹498.35 at the NSE close on 3 November 2026, down 31.2% in a year. Amrutanjan Health Care (NSE: AMRUTANJAN) is worth ₹1,440 crore, trades at a P/E of 23.2 and has closed between ₹487.65 and ₹719.85 over the past 52 weeks. > Amrutanjan Health Care Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. AMRUTANJAN · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹498.35 (−31.2% in a year)
- P/E: 23.2× (lower than 99% of the last 11 years)
- Revenue (Jun 2026): ₹103 Cr (+9.5% on a year ago)
- Profit (Jun 2026): ₹4.4 Cr (−47.4% on a year ago)
- Operating margin: 6.1% (−2.9 points on a year ago)
- ROCE: 25%, FY26
- ROIC: 21.5%, against a 12.0% cost of capital: +9.5 points

The main question: yearly earnings per share moved +13.9% while the share price moved −31.2%. ## What is the Amrutanjan Health Care share price today? Amrutanjan Health Care Ltd's share price was ₹498.35 at the close on 3 November 2026. It has been falling for 46 weeks. That is 9.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹488 and ₹720, and at that close it sat 5% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row. Over the last 11 years the share price moved +141% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Amrutanjan Health Care this quarter? Three changes stood out: profit fell in the June 2026 quarter, revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row. 1. Profit fell in the June 2026 quarter Profit was ₹4 crore, -47.4% on a year earlier (₹8 crore), after 7 quarters of growth. 2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹103 crore, +9.5% on a year earlier. 3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 13% to 6.9% of the company by the September 2026 quarter. ## What are Amrutanjan Health Care's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Amrutanjan Health Care reported revenue of ₹103 crore, up 9.5% from ₹94.0 crore a year earlier, and a profit of ₹4.37 crore, down 47.4% from ₹8.31 crore. ### Amrutanjan Health Care results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹103 crore | ₹94.0 crore | +9.5% |
| Profit | ₹4.37 crore | ₹8.31 crore | −47.4% |
| Earnings per share | ₹1.51 | ₹2.87 | −47.4% |
| Operating margin | 6.1% | 9.0% | −2.9 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Amrutanjan Health Care share price history? Amrutanjan Health Care closed at ₹498.35 on 3 November 2026, down 31.2% from ₹724.10 a year earlier (31 October 2025) and down 48.9% over five years. Its highest weekly close since March 2016 was ₹975.00 on 4 November 2021. ### Amrutanjan Health Care share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹487.65 | +2.2% |
| 1 month ago · 1 Oct 2026 | ₹513.80 | −3.0% |
| 6 months ago · 30 Apr 2026 | ₹571.20 | −12.8% |
| 1 year ago · 31 Oct 2025 | ₹724.10 | −31.2% |
| 3 years ago · 3 Nov 2023 | ₹604.70 | −17.6% |
| 5 years ago · 4 Nov 2021 | ₹975.00 | −48.9% |
| 10 years ago · 4 Nov 2016 | ₹287.90 | +73.1% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹207.20 | +140.5% |
| Highest weekly close since March 2016 · 4 Nov 2021 | ₹975.00 | −48.9% |
| Lowest weekly close since March 2016 · 27 May 2016 | ₹199.40 | +149.9% |
| 52-week high (weekly close) · 14 Nov 2025 | ₹719.85 | −30.8% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹487.65 | +2.2% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Amrutanjan Health Care? 3 Nov 2026: Amrutanjan Health Care closed at ₹498.35, up 2.2% on the week and down 3.0% on the month. 11 Sep 2026: ex-date for a dividend of ₹2.90 a share. ### Earlier

- Results for April to June 2026: Revenue up 9.5% and profit down 47.4% on a year earlier. - 6 Feb 2026: ex-date for an interim dividend of ₹1 a share, record date 7 Feb 2026. - 18 Nov 2025: ex-date for an interim dividend of ₹1 a share. ## What dividend does Amrutanjan Health Care pay? Amrutanjan Health Care paid ₹4.90 a share in regular dividends in the 12 months to 4 November 2026 (3 payments), a yield of 0.98% at the ₹498.35 close on 3 November 2026. The last was a dividend of ₹2.90 a share, ex-date 11 September 2026. ### Amrutanjan Health Care dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 11 Sep 2026 | ₹2.90 | Dividend | same day |
| 6 Feb 2026 | ₹1 | Interim | 7 Feb 2026 |
| 18 Nov 2025 | ₹1 | Interim | same day |
| 16 Sep 2025 | ₹2.60 | Dividend | same day |
| 18 Feb 2025 | ₹1 | Interim | same day |
| 22 Nov 2024 | ₹1 | Interim | same day |
| 13 Sep 2024 | ₹2.60 | Dividend | 16 Sep 2024 |
| 20 Feb 2024 | ₹1 | Interim | same day |
| 23 Nov 2023 | ₹1 | Interim | same day |
| 14 Sep 2023 | ₹2.60 | Dividend | same day |
| 24 Feb 2023 | ₹1 | Interim | same day |
| 14 Nov 2022 | ₹1 | Interim | 15 Nov 2022 |
| 14 Sep 2022 | ₹2.60 | Dividend | n/a |
| 18 Feb 2022 | ₹1 | Interim | 21 Feb 2022 |
| 16 Nov 2021 | ₹1 | Interim | 17 Nov 2021 |
| 15 Sep 2021 | ₹2.60 | Dividend | 16 Sep 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Amrutanjan Health Care Ltd paid out 24% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Amrutanjan Health Care on? Amrutanjan Health Care is on 2 of our India lists: 52 week high & low and Pharma stocks. - [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Pharma stocks Market value (₹ crore): 1435.2771569515755](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Amrutanjan Health Care profitable? Amrutanjan Health Care Ltd earned ₹4.4 Cr of net profit in the Jun 2026 quarter, −47.4% on the same quarter a year earlier. Full-year FY26 profit was ₹58.0 Cr. Over 10 years profit has grown 10.2% a year on average. That is 4.2% of the quarter's revenue. The same quarter a year earlier earned ₹8.3 Cr. For the full year, FY26 profit was ₹58.0 Cr (+13.7% on the year before). Why profit moved: revenue changed +9.5% on a year earlier and the margin moved −2.9 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −5.3% and revenue +10.5%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Amrutanjan Health Care make, and is it growing? Amrutanjan Health Care Ltd reported ₹103 Cr of revenue in the Jun 2026 quarter, +9.5% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 11.2% a year on average. The last full year, FY26, came in at ₹503 Cr. The last four reported quarters add to ₹511 Cr. FY26 revenue was ₹503 Cr, +11.3% on the year before. Recent pace: the last four quarters grew +10.5% on average, against 11.2% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.7%, against +9.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −1.0%, against +12.6% a year (rolling over). ## How much of every ₹100 of sales does Amrutanjan Health Care keep? Amrutanjan Health Care Ltd's operating margin was 6.1% in the Jun 2026 quarter, 2.9 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 22.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −2.9 percentage points on the year while gross margin changed −0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Amrutanjan Health Care's profit turning into cash? Over the last 3 years, 75% of Amrutanjan Health Care Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹36.0 Cr of operating cash against ₹58.0 Cr of profit. After ₹98.0 Cr of spending on assets, free cash was −₹62.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 75% of profit came in as cash: the cash cycle got 35 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 35 days longer. The next section looks at where the cash is stuck. ## Where does Amrutanjan Health Care's cash go? Amrutanjan Health Care Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −6 days in FY26, up from −41 days in FY21. It spent ₹126 Cr on assets over the last 3 years. Customers take 44 days to pay, and stock sits for 56 days on average. At FY26 sales of ₹503 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly −₹8.0 Cr is tied up in the business at any time. FY26: customers took 44 days to pay and stock sat for 56 days, about 1.8 months of sales sitting as stock, for a full cycle of −6 days, longer than FY21's −41. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 56 days. Customers pay about 44 days after that. Suppliers are paid at 106 days. Together that makes the −6-day cycle. Spending on assets: ₹126 Cr over the last 3 years, against ₹19.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹106 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Amrutanjan Health Care's P/E ratio, and how does it compare with its own history? Amrutanjan Health Care Ltd's P/E is 23.2×, about the lowest it has ever been. Its usual P/E (the middle reading) is 40.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹18.67. Why the multiple is where it is: over the past year earnings per share moved +13.9% while the price moved −31.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −12.6% a year; about −1.2% a year came from earnings growth and about −11.4 percentage points from the multiple (the market paying less); over 10 years the price moved +5.6% a year; about +10.8% a year came from earnings growth and about −5.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Amrutanjan Health Care business getting better or worse? Amrutanjan Health Care Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +19.3% at its peak to −1.0% now), while ROCE is still 20.3%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Amrutanjan Health Care earn on its capital? Amrutanjan Health Care Ltd earned a ROCE of 25% in FY26. That is up from a low of 19% in FY23. Its return on capital used (ROIC) is 9.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 11.5% net margin and 0.99× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.5% net margin × 0.99× asset turnover × 1.38× leverage (assets divided by equity) ≈ 15.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 21.5% − 12.0% = +9.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 21.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 28.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Amrutanjan Health Care have too much debt? Amrutanjan Health Care Ltd has total debt of ₹2.0 Cr against shareholder equity of ₹370 Cr as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Amrutanjan Health Care shareholding pattern? Domestic institutions cut their stake in Amrutanjan Health Care Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 6.9% of the company. Foreign institutions moved +1.1 points over the same period, to 3.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.7 points over 8 quarters, to 6.9%; Foreign institutions: +1.1 points over 8 quarters, to 3.5%; Promoters: +0.0 points over 8 quarters, to 46.5%. Why the owners changed: domestic institutions drove it (−3.7 points), with the other side taken by foreign institutions (+1.1 points). They reduced their stake. ## How far is Amrutanjan Health Care from balance-sheet trouble? For Amrutanjan Health Care Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Amrutanjan Health Care rank in its industry? 44.9 out of 100, rank 29 of 44 in Pharma - Formulators, with 96% of the evidence available. Amrutanjan Health Care Ltd scores 44.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 29. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 10.2 + 14.9 + 14 + 5.8 = 44.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Amrutanjan Health Care compared with? Amrutanjan Health Care ranks 29 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 44.9 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. Amrutanjan Health Care Ltd this page AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.2/35 · Revenue 10.7% · Profit -1.1% · Operating margin change -2.9 points · 88% evidence Capital efficiency 14.9/25 · ROCE 24.8% · Operating margin 6.1% · 100% evidence Valuation 14.0/20 · P/E 23.1× · PEG 1.69 · 100% evidence Relative strength 5.8/20 · Lead over its industry -28.3% · Lead over NIFTY 500 -8.3% · 1 year -31.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.2 + 14.9 + 14 + 5.8 = 44.9 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Amrutanjan Health Care in size? Amrutanjan Health Care is the 36th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sai Parenterals, Indoco Remedies and Accent Microcell. Just below it: Bharat Parenterals, Bafna Pharmaceuticals and Bajaj Healthcare. ### Pharma - Formulators companies close in size

1. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) ₹2,306 crore
2. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) ₹1,923 crore
3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ₹1,533 crore
4. Amrutanjan Health Care Ltd ₹1,436 crore
5. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) ₹1,399 crore
6. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
7. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Magellanic Cloud Ltd](https://www.sectoralpha.in/stocks/magellanic-cloud-ltd) ₹1,440 crore · IT - Software
2. [Texmaco Infrastructure & Holdings Ltd](https://www.sectoralpha.in/stocks/texmaco-infrastructure-holdings-ltd) ₹1,439 crore · Diversified
3. Amrutanjan Health Care Ltd ₹1,436 crore
4. [Tinna Rubber & Infrastructure Ltd](https://www.sectoralpha.in/stocks/tinna-rubber-infrastructure-ltd) ₹1,436 crore · Rubber Processing/Rubber Products
5. [Jindal Drilling & Industries Ltd](https://www.sectoralpha.in/stocks/jindal-drilling-industries-ltd) ₹1,434 crore · Oil Drilling & Exploration

## What else do people ask about Amrutanjan Health Care? ### What were Amrutanjan Health Care's latest quarterly results? Amrutanjan Health Care Ltd reported revenue of ₹103 Cr and net profit of ₹4.4 Cr for the Jun 2026 quarter. Revenue rose 9.5% and profit fell 47.4% compared with a year earlier. Earnings per share were ₹1.51. The operating margin was 6.1%, 2.9 percentage points lower than a year earlier (as of 3 November 2026). ### What is Amrutanjan Health Care's market cap? Amrutanjan Health Care Ltd's market capitalisation is ₹1,440 Cr at a share price of ₹498.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Amrutanjan Health Care performing? Amrutanjan Health Care Ltd's share price has been falling for 46 weeks. In its latest quarter, revenue rose 9.5% and profit fell 47.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 3 weeks running (as of 3 November 2026). ### Will Amrutanjan Health Care's share price go up? This page does not forecast Amrutanjan Health Care Ltd's share price. What it shows instead: the share price is ₹498.35, and it has been falling for 46 weeks. Its P/E of 23.2× is higher than 1% of its own last 11 years (as of 3 November 2026). ### Where is Amrutanjan Health Care in its business cycle? Amrutanjan Health Care Ltd's FY26 operating margin was 15.0%, against a 13-year range of 12.0% to 22.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 6.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Amrutanjan Health Care story? The main question: yearly earnings per share moved +13.9% while the share price moved −31.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Amrutanjan Health Care a stock worth studying right now? What the numbers show: Amrutanjan Health Care Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.